Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Accumulated Expenses (2023 - 2025)

Connect Biopharma Holdings' Accumulated Expenses history spans 2 years, with the latest figure at $8.9 million for Q3 2025.

  • For Q3 2025, Accumulated Expenses changed N/A year-over-year to $8.9 million; the TTM value through Sep 2025 reached $8.9 million, changed N/A, while the annual FY2024 figure was $7.8 million, N/A changed from the prior year.
  • Accumulated Expenses for Q3 2025 was $8.9 million at Connect Biopharma Holdings, up from $7.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $8.9 million in Q3 2025 and bottomed at $7.8 million in Q4 2024.